Publications by authors named "A Volgina"
Article Synopsis
- Mutations in a protein called calreticulin (mutCALR) cause blood disorders known as myeloproliferative neoplasms (MPNs), but there aren’t any treatments specifically targeting this mutation.
- A new antibody called INCA033989 can specifically attack cells with the mutCALR mutation, stopping them from growing and causing problems.
- In tests on mice, INCA033989 not only prevented issues like high blood cell counts but also showed it could help treat the disease without harming normal blood cell production.
Article Synopsis
- A new small-molecule PD-L1 inhibitor, INCB086550, has been developed, showing promising results in blocking the PD-L1/PD-1 interaction which is significant in cancer treatment.
- In lab tests, INCB086550 effectively prevents PD-L1 from binding to PD-1, activates immune responses, and shows potential for enhancing antitumor activity.
- Initial clinical trials indicate that this drug may improve immune activation and control tumor growth, suggesting it could serve as a viable alternative to existing antibody therapies for cancer.
Immune checkpoint inhibitors demonstrate clinical activity in many tumor types, however, only a fraction of patients benefit. Combining CD137 agonists with these inhibitors increases anti-tumor activity preclinically, but attempts to translate these observations to the clinic have been hampered by systemic toxicity. Here we describe a human CD137xPD-L1 bispecific antibody, MCLA-145, identified through functional screening of agonist- and immune checkpoint inhibitor arm combinations.
View Article and Find Full Text PDFAlterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes. Pharmacological targeting of FGFRs may therefore provide therapeutic benefit to selected cancer patients, and proof-of-concept has been established in early clinical trials of FGFR inhibitors. Here, we present the molecular structure and preclinical characterization of INCB054828 (pemigatinib), a novel, selective inhibitor of FGFR 1, 2, and 3, currently in phase 2 clinical trials.
View Article and Find Full Text PDF